Health Economics›Cholangiocarcinoma›Metastatic disease second-line

Metastatic disease second-line

Cholangiocarcinoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6 Variant #02	—	R 2 617	14d	~8.4 mo	~12.7 mo	~6	~R 15 700 PFS proxy · indirect	15
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 2 054	14d	—	~11.8 mo	~2	~R 4 107 PFS proxy · indirect	3
FULV and nanoliposomal Irinotecan Variant #01 Partial	—	R 1 170	14d	~7.1 mo	~7.1 mo	~2	~R 2 339 PFS proxy · indirect	4
FULV Variant #29	—	R 806	14d	~5.6 mo	~13.1 mo	~5	~R 4 028 PFS proxy · indirect	15

4 of 4 regimens shown